Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

在市场强劲势头推动下，iBio Inc.股价飙升至52周新高，触及5.03美元。对于这家专注于开发和生产植物制药的生物技术公司来说，这一价格水平代表着重要里程碑。根据 InvestingPro 数据显示，该股票的贝塔系数为-3.29，往往与市场趋势相反。过去一年，iBio股价实现了221.37%的显著回报，尤其在过去六个月中表现强劲，涨幅达95.83%。虽然收入增长达650%， ...

The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, ...

Martin Brenner, Ph.D. “Following more recent developments, we also want to highlight the significant strides we have made in advancing our preclinical pipeline with the in-licensing of potentially ...

Discovered a novel antibody targeting activin E in collaboration with AstralBio, leveraging iBio’s Machine-Learning Antibody Engine to overcome significant technical challenges, demonstrating ...